





SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero - Universitaria di Parma Sleep microstructure in Parkinson's disease related dementia: is cyclic alternating pattern a neurophysiological marker of neurodegeneration?

R. Cremascoli ^{1,2}, L. Priano ^{1,2}, B. Dal Fabbro³, N. Azzi ⁴, C. Mutti ⁴, L. Bianchi ¹, C. Chiello ³, D.


Sandri², P. Cipresso^{1,2}, F. Borghesi¹, C. Lombardi¹, M. Terzaghi³, A. Mauro^{1,2}, L. Parrino⁴

1 Istituto Auxologico Italiano, IRCCS, Verbania, Italy;
2 University of Turin, Turin, Italy;
3 IRCCS Mondino Foundation, Pavia, Italy,
4 University Hospital of Parma, Parma, Italy

INTRODUCTION AND METHODS

Sleep microstructure, specifically called cyclic alternating pattern or CAP, could be more informative than standard sleep stage scoring about neurophysiological alterations in neurodegenerative diseases. In fact, American Academy of Sleep Medicine criteria for sleep scoring are designed for healthy people and their use in patients affected by neurodegenerative diseases often result in not reliable sleep parameters and poor specific neurophysiologic markers. The main aim of this study was to evaluate CAP in PD patients with different degrees of cognitive impairment, in order to provide an objective measure of sleep microstructure alteration and evaluate possible associations with neurodegeneration progression.

Patients affected by PD with cognitive impairment were recruited at the Neurology Units of Hospital Auxologico Piancavallo of Verbania and C. Mondino Institute. PD diagnosis was based on Movement Disorder Society clinical diagnostic criteria.



Patients underwent a complete neuropsychological test battery. Mild cognitive impairment (MCI) and dementia diagnosis were based on Movement Disorder Society task force guidelines. All patients underwent an in-lab full-night Videopolysomnography (PSG). CAP scoring of each patient was revised by an evaluator of the Sleep Medicine Unit of Parma. Exclusion criteria for both groups included moderate/severe depression or agitation not under control with psychoactive drugs, significant pain disturbances, an apnea-hypopnea index (AHI) > 15 per hour, a periodic limb movement index during sleep (PLMI) > 15 per hour.

<u>RESULTS</u>

We recruited 16 PDMCI patients and 16 PDD patients, comparable for age and sex (*table 1*). Concerning sleep macrostructure both groups showed poor sleep efficiency and high standard deviations in sleep parameters. REM sleep (% of TST) was significantly reduced in PDD compared to PDMCI (*p=0,002, table 2*). CAP rate was significantly reduced in both groups compared to normative values, with a greater decrease in PDD compared to PDMCI (*table 3*). The proportion of CAP A1, A2 and A3 phases were reduced in both groups, and the same trend of reduction in PDD compared to PDMCI was found (*table 3*). Furthermore REM sleep time, CAP rate and related component A1, A2 and A3 phases correlated with both MMSEc and several neuropsychological tests (*table 4*). A Binomial logistic regression combining Total REM sleep time and CAP rate related to 1NREM has been built using two models to classify the two patients groups (*table 5-6*). CAP rate % 1 NREM contributed in improving the classification even with respect to accuracy (*figure 1*).

Table 1: Clinical and demographic features of PDMCI and PDD patients Group (0 PDD - 1 PDMCI) SD 6.910 PD-D Age (y) 7.096 PD-MCI SEX (0 F - 1 M) PD-D M 7/17 PD-MCI M 6/15 4.074 Disease duration (years) PD-D 7.800 PD-MCI 10.133 6.739 MMSEc PD-D 21.3 3.436

oup Descriptives						
	Group	N	Mean	Median	SD	SE
Wake After Onset Sleep (min)	PDD	16	205.2	166.00	153.26	37.17
	PD MCI	16	213.0	199.80	123.5	31.88
Total Sleep Time (min)	PDD	16	400.9	413.00	188.86	45.81
	PD MCI	16	394.7	395.00	112.7	29.09
Sleep latency (min)	PDD	16	79.0	24.10	114.39	27.74
	PD MCI	16	75.9	4.20	152.7	39.42
Number Of Awakenings (n)	PDD	16	16.1	10.00	14.16	3.43
	PD MCI	16	23.6	23.00	15.4	3.99
itage REM Latency from Sleep Diset	PDD	16	152.7	149.50	139.30	34.82
	PD MCI	16	167.7	122.00	113.9	29.41
SLEEP EFFICIENCY (%)	PDD	16	58.2	59.10	25.84	6.27
	PD MCI	16	60.5	65.30	15.4	3.97
STAGE N1 (%TST)	PDD	16	13.1	3.30	23.82	5.78
	PD MCI	16	14.2	7.40	17.7	4.56
STAGE N2 (%TST)	PDD	16	47.1	42.90	16.09	3.90
	PD MCI	16	55.5	47.60	36.4	9.39
STAGE N3 (%TST)	PDD	16	29.8	33.50	13.82	3.46
	PD MCI	16	28.9	23.70	19.9	5.15
STAGE REM (%TST) *	PDD	16	11.7	11.70	7.65	1.86
	PD MCI	16	24.3	25.50	12.9	3.33
RBD (n)	PDD	16	7 (43.7%)			
	PD MCI	16	4 (25%)			

Table 3: Sleep microstructure parameters in PD MCI and PDD patients:groups' descriptives

PD-D PD-D PD-MCI PD-D PD-MCI PD-D PD-MCI PD-D PD-D PD-D PD-D	17 15 17 15 17 15 17 15 17 15	3.765 11.673 82.265 88.127 173.529 195.600 31.741 40.880 82.947 89.367	1.60 4.600 78.80 90.100 173.00 192.000 31.70 38.800 92.80 93.300	5.12 15.775 60.65 44.723 132.25 109.105 23.22 21.765 25.22 11.096	1.24 4.07 14.70 11.54 32.07 28.17 5.63 5.62 6.11 2.86
PD-D PD-MCI PD-D PD-MCI PD-D PD-MCI PD-D PD-MCI	17 15 17 15 17 15 17 15	82.265 88.127 173.529 195.600 31.741 40.880 82.947	78.80 90.100 173.00 192.000 31.70 38.800 92.80	60.65 44.723 132.25 109.105 23.22 21.765 25.22	14.70 11.54 32.07 28.17 5.63 5.62 6.11
PD-MCI PD-D PD-MCI PD-D PD-MCI PD-D PD-MCI	15 17 15 17 15 17 15	88.127 173.529 195.600 31.741 40.880 82.947	90.100 173.00 192.000 31.70 38.800 92.80	44.723 132.25 109.105 23.22 21.765 25.22	11.54 32.07 28.17 5.63 5.62 6.11
PD-D PD-MCI PD-D PD-MCI PD-D PD-MCI	17 15 17 15 17 15	173.529 195.600 31.741 40.880 82.947	173.00 192.000 31.70 38.800 92.80	132.25 109.105 23.22 21.765 25.22	32.07 28.17 5.63 5.62 6.11
PD-MCI PD-D PD-MCI PD-D PD-MCI	15 17 15 17 15	195.600 31.741 40.880 82.947	192.000 31.70 38.800 92.80	109.105 23.22 21.765 25.22	28.17 5.63 5.62 6.11
PD-D PD-MCI PD-D PD-MCI	17 15 17 15	31.741 40.880 82.947	31.70 38.800 92.80	23.22 21.765 25.22	5.63 5.62 6.11
PD-MCI PD-D PD-MCI	15 17 15	40.880 82.947	38.800 92.80	21.765 25.22	5.62 6.11
PD-D PD-MCI	17 15	82.947	92.80	25.22	6.11
PD-MCI	15				
		89.367	93.300	11 006	2.00
				11.090	2.00
	17	15.971	12.90	12.36	2.99
PD-MCI	15	17.500	13.600	9.621	2.48
PD-D	17	5.729	4.60	5.01	1.21
PD-MCI	15	6.160	4.500	3.768	0.97
PD-D	17	3.465	2.80	2.82	0.68
PD-MCI	15	6.820	5.100	7.700	1.98
PD-D	17	1.971	0.00	3.66	0.88
	PD-MCI PD-D PD-MCI	PD-MCI 15 PD-D 17 PD-MCI 15 PD-D 17	PD-MCI 15 6.160 PD-D 17 3.465 PD-MCI 15 6.820 PD-D 17 1.971	PD-MCI 15 6.160 4.500 PD-D 17 3.465 2.80 PD-MCI 15 6.820 5.100 PD-D 17 1.971 0.00	PD-MCI 15 6.160 4.500 3.768 PD-D 17 3.465 2.80 2.82 PD-MCI 15 6.820 5.100 7.700 PD-D 17 1.971 0.00 3.66

	PD-MCI	16	25.200	25	10.178	
Ldopa equivalent dose	PD-D	16	722.667	765	372.697	
	PD-MCI	16	434.067	433	322.728	

1.812

8.246

PD-MCI

PD-D

UPDRS III score




Table 4: Correlations between neuropsychological tests andsleep microstructure

		CAP_Rate % NREM_all phases	CAP_Rate % NREM_phase A1	CAP_Rate % NREM_phase A2	CAP_Rate % NREM_phase A3	MMSE	Verbal Span
CAP_Rate % NREM_all phases	Pearson's r	_					
	p-value	_					
CAP_Rate % NREM_phase A1	Pearson's r	0.902 ***	_				
	p-value	< .001	—				
CAP_Rate % NREM_phase A2	Pearson's r	0.888 ***	0.754 ***	_			
	p-value	< .001	< .001	—			
CAP_Rate % NREM_phase A3	Pearson's r	0.591 ***	0.216	0.454 **	_		
	p-value	< .001	0.234	0.009	_		
MMSE	Pearson's r	0.298	0.218	0.144	0.365 *	_	
	p-value	0.098	0.231	0.432	0.040	—	
Verbal Span	Pearson's r	0.037	-0.176	-0.014	0.455 *	0.446 *	_
	p-value	0.846	0.353	0.942	0.011	0.013	—
Raven Matrixes	Pearson's r	0.459 *	0.274	0.463 **	0.498 **	0.549 **	0.450 *
	p-value	0.011	0.144	0.010	0.005	0.002	0.013

Table 5. Improvement of the model from 1 (%TST_REM) to 2 (%TST_REM + CAP Rate % N1).


/lodel Fit	Measures					
Model	Deviance	AIC	BIC	R^{2}_{McF}	R ² cs	R^2_N
1	34.0	38.0	41.0	0.231	0.273	0.364
2	31.7	37.7	42.1	0.284	0.325	0.434

Table 6. Binomial logistic regression measured by %TST_REM andCAP Rate % N1 with Group (PDMCI vs. PDD) as the dependent variable.

Predictor	Estimate	SE	Z	р
Intercept	-2.6505	1.0183	-2.60	0.009
%TST_REM	0.1145	0.0468	2.45	0.014
CAP Rate % N1_all phases	0.0937	0.0739	1.27	0.205

Note. Estimates represent the log odds of "Group (0 PDD - 1 PDMCI) = PD-MCI" vs. "Group (0 PDD - 1 PDMCI) = PD-D"

Figure 1. Specificity vs. Sensitivity classifying the two groups (PDMCI vs. PDD) with REM sleep (%TST) and CAP Rate % N1 in model 2 as descripted in table 8 and 9.



CONCLUSION

Combining sleep microstructure parameters and total REM sleep time seemed to give the best accuracy in predicting the degree of cognitive impairment. Despite the small sample size, sleep microstructure proved to add more information about neurodegeneration progression in PD related dementia. In this view, it could become a non-invasive and cost effective neurophysiological marker in neurodegenerative diseases.

REFERENCES

- Terzano, M.G., Parrino, L., Smerieri, A., Chervin, R., Chokroverty, S., Guilleminault, C. et al. Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Medicine 3 (2002) 187–199. doi: 10.1016/s1389-9457(01)00149-6
- Priano, L., Bigoni, M., Albani, G., Sellitti, L., Giacomotti, E., Picconi, R. et al. Sleep microstructure in Parkinson's disease: cycling alternating pattern (CAP) as a sensitive marker of early NREM sleep instability. Sleep Med (2019) Sep;61:57-62. 10.1016/j.sleep.2019.03.025
- Litvan I., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) March ; 27(3): 349–356. doi:10.1002/mds.24893.

CONTACTS



Please do not hesitate to contact me for further information at this email address: r.cremascoli@auxologico.it

https://esleepeurope.eu/